Key result
Pharmacological and device therapies for heart failure should generally apply similarly to men and women, though women may derive more benefit from ARBs and men from ACE inhibitors.
Why the study?
Does sex influence the response to pharmacological and device therapies in patients with heart failure?
Does sex influence the response to pharmacological and device therapies in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Heart failure therapies generally apply similarly to both sexes, though women may derive more benefit from ARBs and men from ACE inhibitors, highlighting the need for better representation of women in future trials.
Sex-related differences in clinical and laboratory characteristics, course and prognosis are well documented in patients with heart failure. However, most information regarding heart failure therapies has been obtained from studies conducted primarily in men. Reviewing the existing literature indicates that the recommendations regarding pharmacological and device therapies should apply similarly to men and women. One possible exception, however, is the possibility of more benefit derived from angiotensin receptor blockers in women, and from angiotensin converting enzyme inhibitors in men. Future clinical trials should be conducted either exclusively in women or have a larger representation of women to insure the adequate assessment of the potential benefit versus risk in women.
No takes yet. Share an insight, caveat, or question.
Ghali et al. (2008) conducted a review in Heart failure. Pharmacological and device therapies was evaluated. Pharmacological and device therapies for heart failure should generally apply similarly to men and women, though women may derive more benefit from ARBs and men from ACE inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: